Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 5/20 | 0.38 |
| ▸ | PRKAG1 | P54619 | 5/20 | 0.38 |
| ▸ | PRKAA2 | P54646 | 5/20 | 0.38 |
| ▸ | PRKAA1 | Q13131 | 5/20 | 0.38 |
| ▸ | PRKAG3 | Q9UGI9 | 5/20 | 0.38 |
| ▸ | PRKAG2 | Q9UGJ0 | 5/20 | 0.38 |
| ▸ | PRKAB1 | Q9Y478 | 5/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.32 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.32 |
| ▸ | RHEB | Q15382 | 1/20 | 0.32 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27283024 | 1.00 | PRKAB2 (0.38) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL30750345 | 0.90 | BTK (0.37) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL27277710 | 0.90 | BTK (0.37) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL30840825 | 0.86 | TRPA1 (0.33) | RHEBTRPA1 | |
| SCHEMBL27265131 | 0.86 | TRPA1 (0.33) | RHEBTRPA1 | |
| SCHEMBL30805103 | 0.86 | TRPA1 (0.33) | RHEBTRPA1 | |
| SCHEMBL31065875 | 0.85 | PRKAB2 (0.41) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| Iodide SCHEMBL30750030 | 0.85 | RHEB (0.30) | RHEBTRPA1 | |
| SCHEMBL30840249 | 0.84 | TRPA1 (0.32) | RHEBTHRATHRBTRPA1 | |
| SCHEMBL27283125 | 0.84 | TRPA1 (0.32) | RHEBTHRATHRBTRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624051-B2 | Macrocyclic compounds, compositions, and methods of using thereof | GENZYME CORPORATION (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260008786-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SCHRODINGER, LLC | 2026-01-08 | — | — | US | disclosed |
| US-20260008785-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SCHRODINGER, LLC | 2026-01-08 | — | — | US | disclosed |
| EP-4583972-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | Sionna Therapeutics Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250197422-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SCHRODINGER, LLC | 2025-06-19 | — | — | US | disclosed |
| WO-2024054840-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SIONNA THERAPEUTICS (US) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624051-B2 | Macrocyclic compounds, compositions, and methods of using thereof | CFTR, ABCC3, ABCD3 | PRKAB2 408/4885PRKAG1 494/4885PRKAA2 484/4885 |
| US-20260008786-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCC3, ABCD3 | PRKAB2 408/4885PRKAG1 494/4885PRKAA2 484/4885 |
| US-20260008785-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCC3, ABCD3 | PRKAB2 386/4885PRKAG1 474/4885PRKAA2 543/4885 |
| US-20250197422-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCB1, PKD1 | PRKAB2 701/4885PRKAG1 425/4885PRKAA2 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.